Sivextro

Active Ingredient(s): Tedizolid Phosphate
FDA Approved: * June 20, 2014
Pharm Company: * CUBIST PHARMS
Category: Skin Care

Tedizolid (formerly torezolid, trade name Sivextro),[3] is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid. It was developed by Cubist Pharmaceuticals, following acquisition of Trius Therapeutics (originator: Dong-A Pharmaceuticals), and is marketed for the treatment of acute bacterial skin and skin structure infections (also known as complicated skin and skin-structure infections (cSSSIs)).[4]... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Sivextro 200 mg Intravenous Powder, for Solution

NDC: 67919-040

Labeler:

Cubist Pharmaceuticals, Inc.

Sivextro 200 mg Oral Tablet, Coated

NDC: 67919-041

Labeler:

Cubist Pharmaceuticals, Inc.

Sivextro 200 mg Oral Tablet, Film Coated

NDC: 72000-310

Labeler:

Nabriva Therapeutics Us, Inc.

Sivextro 200 mg/4ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 72000-320

Labeler:

Nabriva Therapeutics Us, Inc.